Sign in

CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
471851754
Phone
240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
Open-market buys, last 90 days
$949,381
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Ciongoli Gregory Austin +$949K Director 1 filing

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2020-03-31 Vasista Vittal Chief Financial Officer Option exercise +10,000 $0.85 $9K 220,215
2020-03-31 Vasista Vittal Chief Financial Officer Option exercise · Employee Stock Option (Right to Buy) −10,000 74,900
2020-02-11 Simpson Curran SVP, Product Development & CTO Option exercise +6,633 $22.00 $146K 16,512
2020-02-11 Simpson Curran SVP, Product Development & CTO Sale −8,872 $50.13 $445K 7,640
2020-02-11 Simpson Curran SVP, Product Development & CTO Sale −3,692 $51.37 $190K 3,948
2020-02-11 Simpson Curran SVP, Product Development & CTO Option exercise · Stock Option (Right to Buy) −6,633 0
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise +4,253 $19.50 $83K 26,901
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise +14,928 $22.00 $328K 41,829
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise +12,479 $35.80 $447K 54,308
2020-02-10 Simpson Curran SVP, Product Development & CTO Sale −44,429 $50.22 $2.2M 9,879
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise · Stock Option (Right to Buy) −12,479 27,500
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise · Stock Option (Right to Buy) −14,928 6,633
2020-02-10 Simpson Curran SVP, Product Development & CTO Option exercise · Stock Option (Right to Buy) −4,253 8,125
2020-02-10 Vasista Vittal Chief Financial Officer Option exercise +3,000 $13.09 $39K 225,021
2020-02-10 Vasista Vittal Chief Financial Officer Sale −677 $49.05 $33K 224,344
2020-02-10 Vasista Vittal Chief Financial Officer Sale −14,129 $50.12 $708K 210,215
2020-02-10 Vasista Vittal Chief Financial Officer Option exercise · Employee Stock Option (Right to Buy) −3,000 26,374
2020-02-10 HAYDEN DONALD J JR Director Option exercise +24,800 $0.85 $21K 24,800
2020-02-10 HAYDEN DONALD J JR Director Sale −24,800 $50.11 $1.2M 0
2020-02-10 HAYDEN DONALD J JR Director Option exercise · Stock Option (Right to Buy) −24,800 129,100

Page 23 of 25 · 494 trades